Recently, a video of Cheng, the sales director of Novo Nordisk China, being protested by a woman in red at an academic conference has been circulating online, causing heated discussions. Afterwards, Novo Nordisk replied to the media that it was "completely a personal dispute among employees.".
According to the online video, on November 23, at the branch venue of the 25th National Academic Conference of the diabetes Branch of the Chinese Medical Association held in Wuhan International Conference Center, a woman in red held a microphone and shouted about her emotional dispute with a member of Novo Nordisk Project, and was immediately invited out of the venue by the conference staff.
On the afternoon of November 24th, a staff member of the Enterprise Exchange Department of Novo Nordisk confirmed to the media that Mr. Cheng is an employee of the company and the Sales Director of the South China region. He stated that "it is completely a personal dispute among employees, and our company will continue to pay attention and further understand the situation.".
Another online email screenshot shows that it is suspected that the woman claimed to have evidence in an internal email of the company, intending to expose the issue of Mr. Cheng. On the evening of the 23rd, a 113 page document was sent out, accusing Mr. Cheng of deceiving the company and "uncovering the glamorous veil of Mr. Cheng from Novo Nordisk.". It is reported that there have been relevant documents circulating online before.
Netizens also posted an email response suspected of Mr. Cheng, with screenshots showing that the email stated that Mr. Cheng had been "extorted" a huge sum of money seven years ago. Four years ago, he sued the woman in court and announced in July this year that she had become a "deadbeat". The email also stated that the parties involved will "report a criminal case and request IT to block their email.".
Public information shows that Novo Nordisk was founded in 1923 and is a leading global biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The goal of the enterprise is to promote change to overcome diabetes and obesity, rare blood diseases, endocrine disorders and other serious chronic diseases. Novo Nordisk has approximately 47000 employees in 80 countries and regions worldwide, providing products and services to over 168 countries and regions worldwide.
Since the beginning of this year, the so-called "weight loss miracle drug" Smeglutai has gone viral, causing the stock price of Novo Nordisk to skyrocket. On November 24th, Novo Nordisk's stock price rose 2.12% to close at $105.45 per share, setting a new historical closing high. Novo Nordisk's stock price has risen by 4.00% this week, and has been rising for four consecutive weeks. On the news front, Novo Nordisk stated in a statement that it plans to invest 2.1 billion euros (2.3 billion US dollars) to expand production in France to meet the growing demand for its popular weight loss medication.
According to the financial report, Novo Nordisk achieved sales revenue of DKK 166.398 billion in the first three quarters of this year, a year-on-year increase of 29%; The net profit was 61.72 billion Danish kroner, a year-on-year increase of 47%. From the product perspective, the GLP-1 inhibitor Smegglutide has achieved significant growth.